- Home
- ENTX vs JSPR Comparison
ENTX vs JSPR Comparison
Compare ENTX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- JSPR
- Stock Information
- Founded
- ENTX 2010
- JSPR 2018
- Country
- ENTX Israel
- JSPR United States
- Employees
- ENTX N/A
- JSPR N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTX Health Care
- JSPR Health Care
- Exchange
- ENTX Nasdaq
- JSPR Nasdaq
- Market Cap
- ENTX 90.2M
- JSPR 82.4M
- IPO Year
- ENTX 2018
- JSPR N/A
- Fundamental
- Price
- ENTX $2.10
- JSPR $5.96
- Analyst Decision
- ENTX Strong Buy
- JSPR Strong Buy
- Analyst Count
- ENTX 1
- JSPR 12
- Target Price
- ENTX $10.00
- JSPR $64.44
- AVG Volume (30 Days)
- ENTX 70.9K
- JSPR 452.6K
- Earning Date
- ENTX 03-07-2025
- JSPR 03-07-2025
- Dividend Yield
- ENTX N/A
- JSPR N/A
- EPS Growth
- ENTX N/A
- JSPR N/A
- EPS
- ENTX N/A
- JSPR N/A
- Revenue
- ENTX $99,000.00
- JSPR N/A
- Revenue This Year
- ENTX N/A
- JSPR N/A
- Revenue Next Year
- ENTX N/A
- JSPR N/A
- P/E Ratio
- ENTX N/A
- JSPR N/A
- Revenue Growth
- ENTX 607.14
- JSPR N/A
- 52 Week Low
- ENTX $1.00
- JSPR $4.55
- 52 Week High
- ENTX $3.35
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- ENTX 40.77
- JSPR 34.64
- Support Level
- ENTX $2.20
- JSPR $4.55
- Resistance Level
- ENTX $2.49
- JSPR $6.55
- Average True Range (ATR)
- ENTX 0.22
- JSPR 0.53
- MACD
- ENTX -0.03
- JSPR 0.49
- Stochastic Oscillator
- ENTX 16.13
- JSPR 56.18
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.